-
Something wrong with this record ?
Synthesis and biological activity evaluation of novel 2,6,9-trisubstituted purine conjugates as potential protein kinases inhibitors
K. Vlková, T. Gucký, M. Peřina, E. Řezníčková, V. Kryštof
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Protein Kinase Inhibitors chemical synthesis chemistry pharmacology MeSH
- Cell Cycle Checkpoints drug effects MeSH
- Humans MeSH
- Molecular Structure MeSH
- Cell Line, Tumor MeSH
- Cell Proliferation drug effects MeSH
- Protein Kinases metabolism MeSH
- Antineoplastic Agents chemical synthesis chemistry pharmacology MeSH
- Purines chemical synthesis chemistry pharmacology MeSH
- Drug Screening Assays, Antitumor MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Deregulation of protein kinases is often associated with uncontrolled cell proliferation in various tumours and the inhibition of kinase activity remains an important target for anti-tumour drug development. Here, we report a novel series of 2-aminocyclohexylamino-6-(substituted benzylamino/anilino)-9-cyclopentylpurine derivatives conjugated with putrescine, spermidine or spermine moiety in an effort to expand library of highly potent 2,6,9-trisubstituted purine kinase inhibitors. Presented aniline-type conjugates exhibit significant cytotoxic activity in MV4-11 and EOL-1 cell lines which correlates with FLT3-ITD and PDGFRα inhibition. Furthermore, 6-anilinopurines affected MAPK and STAT pathways in the treated MV4-11 cells and induced cell cycle arrest in the G1 phase. 6-Benzylaminopurines showed comparable CDK2 inhibitory activity to 6-anilinopurines, however, the PDGFRα and FLT3-ITD inhibition was strongly suppressed. Our results show that novel compounds containing aniline in the structure can be involved in the development of potent tyrosine kinase inhibitors with strong activity toward acute myeloid leukemia or chronic eosinophilic leukemia.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010756
- 003
- CZ-PrNML
- 005
- 20220506125815.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bmcl.2022.128603 $2 doi
- 035 __
- $a (PubMed)35124201
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vlková, Kristýna $u Department of Experimental Biology, Palacký University, Šlechtitelů 241/27, Olomouc CZ 783 71, Czech Republic
- 245 10
- $a Synthesis and biological activity evaluation of novel 2,6,9-trisubstituted purine conjugates as potential protein kinases inhibitors / $c K. Vlková, T. Gucký, M. Peřina, E. Řezníčková, V. Kryštof
- 520 9_
- $a Deregulation of protein kinases is often associated with uncontrolled cell proliferation in various tumours and the inhibition of kinase activity remains an important target for anti-tumour drug development. Here, we report a novel series of 2-aminocyclohexylamino-6-(substituted benzylamino/anilino)-9-cyclopentylpurine derivatives conjugated with putrescine, spermidine or spermine moiety in an effort to expand library of highly potent 2,6,9-trisubstituted purine kinase inhibitors. Presented aniline-type conjugates exhibit significant cytotoxic activity in MV4-11 and EOL-1 cell lines which correlates with FLT3-ITD and PDGFRα inhibition. Furthermore, 6-anilinopurines affected MAPK and STAT pathways in the treated MV4-11 cells and induced cell cycle arrest in the G1 phase. 6-Benzylaminopurines showed comparable CDK2 inhibitory activity to 6-anilinopurines, however, the PDGFRα and FLT3-ITD inhibition was strongly suppressed. Our results show that novel compounds containing aniline in the structure can be involved in the development of potent tyrosine kinase inhibitors with strong activity toward acute myeloid leukemia or chronic eosinophilic leukemia.
- 650 _2
- $a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
- 650 _2
- $a kontrolní body buněčného cyklu $x účinky léků $7 D059447
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a inhibitory proteinkinas $x chemická syntéza $x chemie $x farmakologie $7 D047428
- 650 _2
- $a proteinkinasy $x metabolismus $7 D011494
- 650 _2
- $a puriny $x chemická syntéza $x chemie $x farmakologie $7 D011687
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gucký, Tomáš $u Department of Experimental Biology, Palacký University, Šlechtitelů 241/27, Olomouc CZ 783 71, Czech Republic. Electronic address: tomas.gucky@upol.cz
- 700 1_
- $a Peřina, Miroslav $u Department of Experimental Biology, Palacký University, Šlechtitelů 241/27, Olomouc CZ 783 71, Czech Republic
- 700 1_
- $a Řezníčková, Eva $u Department of Experimental Biology, Palacký University, Šlechtitelů 241/27, Olomouc CZ 783 71, Czech Republic
- 700 1_
- $a Kryštof, Vladimír $u Department of Experimental Biology, Palacký University, Šlechtitelů 241/27, Olomouc CZ 783 71, Czech Republic
- 773 0_
- $w MED00000770 $t Bioorganic & medicinal chemistry letters $x 1464-3405 $g Roč. 60, č. - (2022), s. 128603
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35124201 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125808 $b ABA008
- 999 __
- $a ok $b bmc $g 1788742 $s 1161954
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 60 $c - $d 128603 $e 20220203 $i 1464-3405 $m Bioorganic & medicinal chemistry letters $n Bioorg Med Chem Lett $x MED00000770
- LZP __
- $a Pubmed-20220425